Home Cart Sign in  
Chemical Structure| 1115270-63-7 Chemical Structure| 1115270-63-7

Structure of IAXO-102
CAS No.: 1115270-63-7

Chemical Structure| 1115270-63-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

IAXO-102 is a novel small molecule TLR4 antagonist.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of IAXO-102

CAS No. :1115270-63-7
Formula : C35H71NO5
M.W : 585.94
SMILES Code : O([C@H]1[C@H](O[C@@H]([C@H]([C@@H]1OCCCCCCCCCCCCCC)O)CN)OC)CCCCCCCCCCCCCC
MDL No. :MFCD31813901
InChI Key :DJVFNDPRLMVKKO-KJQSSVQNSA-N
Pubchem ID :25222900

Safety of IAXO-102

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of IAXO-102

pyroptosis
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
U937 cells 10 µM 1-hour pretreatment, 36-hour treatment To evaluate the effect of IAXO-102 on cell viability. Results showed that IAXO-102 did not prevent cytostasis induced by LPS, TNF-α, and SN-38. Inflammation. 2023 Feb;46(1):103-114
HT-29 cells 10 µM 1-hour pretreatment, 36-hour treatment To evaluate the effect of IAXO-102 on cell viability. Results showed that IAXO-102 did not prevent cytostasis induced by LPS, TNF-α, and SN-38. Inflammation. 2023 Feb;46(1):103-114
T84 cells 10 µM 1-hour pretreatment, 36-hour treatment To evaluate the effect of IAXO-102 on cell viability. Results showed that IAXO-102 did not prevent cytostasis induced by LPS, TNF-α, and SN-38. Inflammation. 2023 Feb;46(1):103-114
alveolar macrophages 10 µM To verify the involvement of CD14/TLR4 in the effect of ATRA on ALI. Results showed that IAXO-102 (TLR4 inhibitor) significantly reduced TLR4 expression and NF-κB pathway activation, enhanced macrophage phagocytosis, and reduced inflammatory responses. Mol Med Rep. 2021 Dec;24(6):868

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Wistar Albino rats Bilateral renal ischemia-reperfusion injury model Intraperitoneal injection 3 mg/kg Single dose, lasting 1 hour To evaluate the protective effect of IAXO-102 on renal ischemia-reperfusion injury. The results showed that IAXO-102 significantly improved kidney function, reduced histological alterations, and decreased the inflammatory response (IL-1, IL-6, and TNF) caused by IRI. Additionally, IAXO-102 decreased apoptosis by reducing pro-apoptotic Bax and increasing anti-apoptotic Bcl-2 without impacting HSP27. J Med Life. 2023 Apr;16(4):623-630
C57BL/6 mice Colon adenocarcinoma model Intraperitoneal injection 3 mg/kg Once daily for 3 days Evaluate the protective effect of IAXO-102 against CPT-11-induced gastrointestinal toxicity. Results showed IAXO-102 prevented diarrhea and reduced colon tissue injury Cancer Chemother Pharmacol. 2022 Sep;90(3):267-278

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.71mL

0.34mL

0.17mL

8.53mL

1.71mL

0.85mL

17.07mL

3.41mL

1.71mL

References

 

Historical Records

Categories